TrialNCT07659782
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
- Last update posted
- 09/04/2026
- Start
- 07/22/2026
- Sponsor
- Verastem, Inc.
- Specialties
- oncology
Conditions: Non-Small Cell Lung Cancer
Brief summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.